Positive Phase 3 results from Moderna and Merck’s intismeran autogene, a personalized mRNA neoantigen vaccine combined with Keytruda, represent the main catalyst for trader sentiment. The INTerpath-001 trial in 1,137 high-risk melanoma patients showed a 42% reduction in recurrence or death risk versus Keytruda alone at two years (82.2% vs. 70% recurrence-free), with durable benefit confirmed in longer follow-up. Companies are now engaging regulators and preparing a U.S. filing, with analysts projecting possible approval and 2027 launch. Key variables include the FDA’s handling of the combination regimen, individualized manufacturing timelines of roughly six weeks, and whether survival data or confirmatory trials accelerate or delay clearance. Other candidates remain earlier-stage.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於1H6H1D7D30DALL
View resolved

警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions